| Chronic Obstructive Airway Disease
Anoro Ellipta vs Ohtuvayre
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Anoro Ellipta vs Ohtuvayre with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOhtuvayre has a higher rate of injection site reactions vs Anoro Ellipta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ohtuvayre but not Anoro Ellipta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Anoro Ellipta
Ohtuvayre
At A Glance
Oral inhalation
Once daily
LAMA/LABA
Oral inhalation
Twice daily
PDE3/PDE4 inhibitor
Indications
- Chronic Obstructive Airway Disease
- Chronic Obstructive Airway Disease
Dosing
Chronic Obstructive Airway Disease 62.5 mcg umeclidinium and 25 mcg vilanterol (1 actuation of ANORO ELLIPTA 62.5/25 mcg) once daily by oral inhalation; do not use more than 1 time every 24 hours.
Chronic Obstructive Airway Disease 3 mg (one unit-dose ampule) twice daily, once in the morning and once in the evening, via oral inhalation using a standard jet nebulizer with a mouthpiece.
Contraindications
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to umeclidinium, vilanterol, or any excipient
- Use of a long-acting beta2-adrenergic agonist (LABA) without an inhaled corticosteroid (ICS) in patients with asthma
- Hypersensitivity to ensifentrine or any component of this product
Adverse Reactions
Most common (>=1%) Pharyngitis, sinusitis, lower respiratory tract infection, constipation, diarrhea, pain in extremity, muscle spasms, neck pain, chest pain
Serious Serious asthma-related events (hospitalizations, intubations, death), paradoxical bronchospasm, cardiovascular effects, worsening of narrow-angle glaucoma, worsening of urinary retention
Postmarketing Palpitations, blurred vision, eye pain, glaucoma, increased intraocular pressure, anaphylaxis, angioedema, urticaria, dysgeusia, tremor, anxiety, dysuria, urinary retention, dysphonia
Most common (>=1%) Back pain, hypertension, urinary tract infection, diarrhea
Serious Paradoxical bronchospasm, psychiatric events including suicidality
Pharmacology
Umeclidinium is a long-acting muscarinic antagonist (LAMA) that inhibits M3 receptors in airway smooth muscle to produce bronchodilation; vilanterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates adenyl cyclase to increase cyclic AMP, relaxing bronchial smooth muscle and inhibiting mediator release from mast cells.
Ensifentrine is a dual inhibitor of PDE3 and PDE4 enzymes; inhibition results in accumulation of intracellular cAMP and/or cGMP, producing downstream bronchodilatory and anti-inflammatory signaling effects.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Anoro Ellipta
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (11/12)
Ohtuvayre
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Anoro Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
Ohtuvayre
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (1/8)
Humana
Anoro Ellipta
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (1/3)
Ohtuvayre
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Anoro Ellipta.
Cost estimate not availableAssistance Fund: Chronic Obstructive Pulmonary Disease (COPD)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Anoro ElliptaView full Anoro Ellipta profile
OhtuvayreView full Ohtuvayre profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.